Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products
1 February 2023 – the FDA published draft guidance on the design and conduct of externally controlled trials. Submit comments by 2 May 2023.This guidance provides recommendations to sponsors and investigators considering the use of externally controlled clinical trials to provide evidence of the safety and effectiveness of a drug product.
Read more online
